Intervention Protocol

You have free access to this content

Vilanterol and fluticasone for asthma

  1. Colin Powell1,*,
  2. Kerry Dwan2,
  3. Stephen J Milan3,
  4. Nicola Walters4,
  5. Lynne Bax5

Editorial Group: Cochrane Airways Group

Published Online: 7 OCT 2013

DOI: 10.1002/14651858.CD010758


How to Cite

Powell C, Dwan K, Milan SJ, Walters N, Bax L. Vilanterol and fluticasone for asthma (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD010758. DOI: 10.1002/14651858.CD010758.

Author Information

  1. 1

    Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Department of Child Health, Cardiff, UK

  2. 2

    University of Liverpool, Department of Biostatistics, Liverpool, England, UK

  3. 3

    St George's University of London, Population Health Sciences and Education, London, UK

  4. 4

    St George's NHS Healthcare Trust, Chest Unit, London, UK

  5. 5

    Lancashire Care NHS Foundation Trust, Preston, UK

*Colin Powell, Department of Child Health, Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, UK. PowellC7@cardiff.ac.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 7 OCT 2013

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To examine the effects of vilanterol and fluticasone furorate on exacerbations and health-related quality of life (HRQL) in adults and children with chronic asthma compared to placebo.